Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: RTOG 1115: PHASE III TRIAL OF DOSE ESCALATED RADIATION THERAPY AND STANDARD ANDROGEN DEPRIVATION THERAPY (ADT) WITH A GNRH AGONIST VS. DOSE ESCALATED RADIATION THERAPY AND ENHANCED ADT WITH A GNRH AGONIST AND TAK-700 FOR MEN WITH HIGH RISK PROSTATE CANCE

 


RTOG 1115: PHASE III TRIAL OF DOSE ESCALATED RADIATION THERAPY AND STANDARD ANDROGEN DEPRIVATION THERAPY (ADT) WITH A GNRH AGONIST VS. DOSE ESCALATED RADIATION THERAPY AND ENHANCED ADT WITH A GNRH AGONIST AND TAK-700 FOR MEN WITH HIGH RISK PROSTATE CANCE


Trial Focus

Prostate Cancer

Objective

         This is a clinical trial of TAK-700 that will be administered by mouth, which is investigational. It will be given with hormone therapy, admimistered by mouth and injection and radiation therapy and is standard of care.

IRB Protocol #

13-0192

Trial Status

Archived

Principle Investigator

DAVID RABEN

Sponsor

RTOG

Contact

MONICA ROBISCHON at (720) 848-0661 or MONICA.ROBISCHON@UCDENVER.EDU

Location

Dept Of Veterans Affairs Medical Center University of Colorado Hospital Dept Of Veterans Affairs Medical Center University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period to receive hormore therapy for 24 months. Radiation therapy will be given for 2 months or brachytherapy implant treatment for 6 weeks. Group 2 will also receive the investigations drug for 24 months. A follow up period will consist of clinic visits. // Eligibility criteria include but are not limited to men18 years or older with high risk prostate cancer.Eligibility criteria include but are not limited to men18 years or older with high risk prostate cancer.